Skip to main content
Clinical Trials/NCT02898688
NCT02898688
Completed
Not Applicable

A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions

Emory University23 sites in 1 country2,200 target enrollmentJune 12, 2017
ConditionsVaccination

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vaccination
Sponsor
Emory University
Enrollment
2200
Locations
23
Primary Endpoint
Number of women receiving pertussis vaccination
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time. This study builds off of a prior intervention, developed by Emory, at the practice, provider, and patient levels (P3) to develop, implement and evaluate an enhanced intervention (P3+) to improve vaccination uptake among pregnant women, and later, their children.

Detailed Description

This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time. This study uses a multi-level factorial design which randomizes at both the practice and the patient level. Obstetric practices in Georgia and Colorado will be randomized to be either an intervention practice or a control practice. The women recruited in the practices and enrolled in the study will be randomly assigned to the intervention arm or the control arm. Women randomized to the intervention arm will complete a computer-based questionnaire (administered via iPad with a preloaded study app) which asks for their basic demographic and contact information and asks questions about their vaccine knowledge, attitudes, and beliefs. Immediately following the questionnaire, participants will receive the individual level intervention (videos providing information on vaccines) on the same iPad. In order to best answer their questions and not provide information beyond the scope of what the study participants need or want, the videos provided to each participant will be selected based on responses to the survey questions. There are 6 videos: one discusses the dangers of the diseases prevented by vaccines, and the others address specific vaccine concerns (concerns include vaccine ingredients, children receiving simultaneous vaccines (multiple vaccines at one time), and the safety of receiving the tdap or flu vaccine during pregnancy). If the participant does not have any concerns, they will only see the video about dangers of vaccine preventable diseases. Participants expressing concerns in the survey will receive up to two videos addressing those concerns, based on an order of priority determined by the study researchers. Women randomized to the control arm will also complete a computer-based questionnaire which includes their personal information and vaccine knowledge, attitudes, and beliefs questions but will then continue to receive usual prenatal care rather than view informational videos. All enrolled women complete two follow-up surveys when their children are 30 days and 18 months of age.

Registry
clinicaltrials.gov
Start Date
June 12, 2017
End Date
July 6, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Factorial
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Robert Bednarczyk

Assistant Professor

Emory University

Eligibility Criteria

Inclusion Criteria

  • Have not previously participated in this study
  • Currently pregnant
  • Up to 26 weeks gestational age
  • Able to understand and communicate in English

Exclusion Criteria

  • Have received pertussis vaccine during the current pregnancy

Outcomes

Primary Outcomes

Number of women receiving pertussis vaccination

Time Frame: Up to 34 weeks

Whether or not the participant chose to receive the pertussis vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms

Number of women receiving influenza vaccination

Time Frame: Up to 34 weeks

Whether or not the participant chose to receive the flu vaccine during pregnancy (between the baseline visit and birth of infant) will be compared between study arms

Timely childhood vaccinations

Time Frame: 20 months

Childhood vaccination will be assessed as timely uptake of childhood vaccines by calculating average days under-vaccinated. The total number of days under-vaccinated will be divided by the number of vaccines a child should have received, according to the Advisory Committee on Immunization Practices (ACIP) schedule, to give the average number of days under-vaccinated across all recommended vaccines. This can range from 0 to 415 days in the first 20 months of life. The average number of days under-vaccinated will be modeled as a continuous variable, and the distribution of days under-vaccinated will be evaluated, in total and by vaccine where possible, to identify specific patterns of interest for follow-up.

Secondary Outcomes

  • Changes in maternal vaccine attitudes(Up to 106 weeks (baseline visit until 18 months post delivery))
  • Changes in maternal vaccine beliefs(Up to 106 weeks (baseline visit until 18 months post delivery))
  • Changes in maternal vaccine knowledge(Up to 106 weeks (baseline visit until 18 months post delivery))

Study Sites (23)

Loading locations...

Similar Trials